Brancatella Alessandro, Viola Nicola, Santini Ferruccio, Latrofa Francesco
Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Endocrinology Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101742. doi: 10.1016/j.beem.2023.101742. Epub 2023 Feb 5.
Breakdown of self-tolerance to thyroid antigens (thyroperoxidase, thyroglobulin and the thyrotropin-receptor) is the driver of thyroid autoimmunity. It has been suggested that infectious disease might trigger autoimmune thyroid disease (AITD). Involvement of the thyroid has been reported during severe acute respiratory syndrome virus 2 (SARS-CoV-2) infection, in the form of subacute thyroiditis in subjects with mild coronavirus disease 19 disease (COVID-19) and of painless, destructive thyroiditis in hospitalized patients with severe infection. In addition, cases of AITD, both Graves' disease (GD) and Hashimoto's thyroiditis (HT), have been reported in association with (SARS-CoV-2) infection. In this review, we focus on the relationship between SARS-CoV-2 infection and occurrence of AITD. Nine cases of GD strictly related to SARS-CoV-2 infection and only three cases of HT associated to COVID-19 infection have been reported. No study has demonstrated a role of AITD as a risk factor for a poor prognosis of COVID-19 infection.
对甲状腺抗原(甲状腺过氧化物酶、甲状腺球蛋白和促甲状腺激素受体)的自身耐受性破坏是甲状腺自身免疫的驱动因素。有人提出,传染病可能引发自身免疫性甲状腺疾病(AITD)。在严重急性呼吸综合征病毒2(SARS-CoV-2)感染期间,甲状腺受累的情况已有报道,表现为轻度冠状病毒病19(COVID-19)患者出现亚急性甲状腺炎,以及重症感染住院患者出现无痛性、破坏性甲状腺炎。此外,与(SARS-CoV-2)感染相关的自身免疫性甲状腺疾病病例,包括格雷夫斯病(GD)和桥本甲状腺炎(HT)也有报道。在本综述中,我们重点关注SARS-CoV-2感染与AITD发生之间的关系。据报道,有9例GD与SARS-CoV-2感染密切相关,而与COVID-19感染相关的HT仅有3例。尚无研究表明AITD是COVID-19感染预后不良的危险因素。